|Outcome||Relative effect 95%CI||LoD||Trt. better when||I2||k (RCT/OBS)||Bayesian probability||Overall ROB||Publication bias||Degree of certainty||Endpoint importance||Published MA|
|deaths||0.59 [0.22, 1.59]||< 1||0%||1 study (1/-)||85.2 %||some concern||not evaluable||moderate||crucial||-|
|clinical improvement||1.40 [0.79, 2.49]||> 1||0%||1 study (1/-)||87.5 %||some concern||not evaluable||moderate||important||-|
|clinical improvement (28-day)||1.42 [0.65, 3.10]||> 1||0%||1 study (1/-)||81.1 %||some concern||not evaluable||moderate||important||-|
LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.